Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Reata Pharmaceuticals Inc Stock Research

RETA

172.17USD-0.04(-0.02%)Market Closed
Watchlist

Market Summary

USD172.17-0.04
Market Closed
-0.02%

RETA Alerts

  • 5 major insider sales recently.

RETA Stock Price

RETA RSI Chart

RETA Valuation

Market Cap

6.5B

Price/Earnings (Trailing)

-74.04

Price/Sales (Trailing)

4.1K

EV/EBITDA

-77.59

Price/Free Cashflow

-26.01

RETA Price/Sales (Trailing)

RETA Profitability

EBT Margin

-23662.79%

Return on Equity

474.77%

Return on Assets

-78.08%

Free Cashflow Yield

-3.85%

RETA Fundamentals

RETA Revenue

Revenue Y/Y

2.9K%

Revenue Q/Q

100%

RETA Earnings

Earnings (TTM)

-87.6M

Earnings Y/Y

362.39%

Earnings Q/Q

266.21%

Price Action

52 Week Range

172.21
(Low)(High)

Last 7 days

0.1%

Last 30 days

1.8%

Last 90 days

77.3%

Trailing 12 Months

544.3%

RETA Financial Health

Current Ratio

6.09

RETA Investor Care

Shares Dilution (1Y)

3.30%

Diluted EPS (TTM)

-2.98

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for RETA

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-14
Loewen Andrea
sold
-546,181
172
-3,175
svp, global regulatory affairs
2023-09-05
Anand Bhaskar
sold
-68,695
169
-406
svp, chief accounting officer
2023-08-23
ROSE WILLIAM
gifted
-
-
-500,000
-
2023-08-16
WORTLEY MICHAEL D
sold
-67,166
168
-398
chief legal officer
2023-08-16
Soni Manmeet Singh
sold
-295,566
168
-1,755
coo, cfo and president
2023-08-16
Anand Bhaskar
sold
-35,367
168
-210
svp, chief accounting officer
2023-08-16
Bir Dawn Carter
sold
-66,996
168
-398
chief commercial officer
2023-08-16
Meyer Colin John
sold
-100,569
168
-596
chief innovation officer
2023-08-15
WORTLEY MICHAEL D
sold
-136,415
169
-807
chief legal officer
2023-08-15
Meyer Colin John
sold
-362,483
169
-2,144
chief innovation officer

1–10 of 50

Which funds bought or sold RETA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-06
Deep Track Capital, LP
sold off
-100
-66,280,700
-
-%
2023-08-24
PERCEPTIVE ADVISORS LLC
reduced
-69.1
-128,896,000
68,334,200
1.98%
2023-08-21
OSAIC HOLDINGS, INC.
reduced
-34.62
-200,519
551,118
-%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-9.67
39,996
3,129,460
-%
2023-08-21
BOKF, NA
sold off
-100
-2,273
-
-%
2023-08-21
VisionPoint Advisory Group, LLC
new
-
41,090
41,090
0.02%
2023-08-21
Affinity Asset Advisors, LLC
new
-
2,967,550
2,967,550
1.04%
2023-08-17
Orion Portfolio Solutions, LLC
added
0.19
30,064
273,457
-%
2023-08-16
Nuveen Asset Management, LLC
reduced
-15.37
-514,784
9,588,220
-%
2023-08-16
GTS SECURITIES LLC
new
-
798,653
798,653
0.03%

1–10 of 44

Latest Funds Activity

Are funds buying RETA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own RETA
No. of Funds

Schedule 13G FIlings of Reata Pharmaceuticals

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Sep 19, 2023
rose william
8.9%
3,182,950
SC 13D/A
Aug 24, 2023
rose william
9.1%
3,240,950
SC 13D/A
Aug 07, 2023
biogen inc.
23.4%
8,936,791
SC 13D
Aug 01, 2023
cpmg inc
13.2%
4,589,758
SC 13D/A
Jul 31, 2023
rose william
9.2%
3,240,950
SC 13D/A
Jun 26, 2023
adage capital partners gp, l.l.c.
5.24%
1,730,841
SC 13G
May 15, 2023
first light asset management, llc
3.91%
1,290,193
SC 13G/A
Mar 07, 2023
perceptive advisors llc
6.5%
2,083,799
SC 13G
Feb 14, 2023
first light asset management, llc
6.79%
2,155,552
SC 13G/A
Feb 14, 2023
point72 asset management, l.p.
0%
0
SC 13G/A

Recent SEC filings of Reata Pharmaceuticals

View All Filings
Date Filed Form Type Document
Sep 19, 2023
4
Insider Trading
Sep 19, 2023
SC 13D/A
13D - Major Acquisition
Sep 18, 2023
4
Insider Trading
Sep 14, 2023
144
Notice of Insider Sale Intent
Sep 12, 2023
8-K
Current Report
Sep 12, 2023
DEFA14A
DEFA14A
Sep 07, 2023
4
Insider Trading
Sep 05, 2023
144
Notice of Insider Sale Intent
Sep 05, 2023
144
Notice of Insider Sale Intent
Aug 24, 2023
4
Insider Trading

Peers (Alternatives to Reata Pharmaceuticals)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
512.5B
29.5B
3.56% 89.32%
78.88
17.36
1.53% 14.16%
423.3B
97.8B
-2.65% 0.10%
32.43
4.33
2.29% -28.92%
272.8B
58.3B
-2.13% 26.48%
17.88
4.63
2.00% -81.24%
189.8B
77.9B
-9.16% -24.26%
8.84
2.44
-23.04% -26.74%
150.1B
45.2B
-5.06% -15.06%
23.72
3.25
-4.15% 20.34%
MID-CAP
6.5B
-
1.75% 544.26%
-74.04
4.1K
-86.94% 71.24%
4.5B
4.6B
-11.49% -16.32%
-66.69
0.98
6.60% 42.04%
SMALL-CAP
1.9B
627.1M
-7.75% -1.79%
-1.34
3.1
-0.20% -204.67%
1.5B
634.0M
-11.88% -19.94%
34.62
2.37
0.62% -24.59%
832.3M
244.3M
-4.13% 4.68%
4.22
3.41
-39.50% -4.99%
830.8M
109.5M
21.79% -27.57%
-5.79
7.59
-2.66% -32.13%
480.0M
453.3M
110.37% -71.69%
-0.39
1.06
-16.04% 55.90%
479.1M
31.2M
-7.77% -52.62%
-4.55
15.37
407.54% -26.47%
269.4M
54.6M
-13.04% -44.44%
-2.97
4.93
9.39% -179.16%
-
2.2B
- -
-
-
-22.39% 63.59%

Reata Pharmaceuticals News

InvestorsObserver
Where Does Wall Street Think Reata Pharmaceuticals Inc (RETA ....
InvestorsObserver,
6 hours ago
finanznachrichten.de
Digital Journal
The Motley Fool

Returns for RETA

Cumulative Returns on RETA

29.8%


7-Year Cumulative Returns

14.5%


5-Year Cumulative Returns

17.8%


3-Year Cumulative Returns

Risks for RETA

What is the probability of a big loss on RETA?

100%


Probability that Reata Pharmaceuticals stock will be more than 20% underwater in next one year

86.5%


Probability that Reata Pharmaceuticals stock will be more than 30% underwater in next one year.

82.7%


Probability that Reata Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does RETA drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Reata Pharmaceuticals was unfortunately bought at previous high price.

Drawdowns

Financials for Reata Pharmaceuticals

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue---2,216,0003,149,00010,000,00011,459,00011,490,00013,748,0007,758,0008,610,0009,019,0008,499,00015,340,00020,100,00026,517,00032,296,00029,229,00028,967,00053,589,00055,101,00062,483,000
Operating Expenses15.4%376,149,000325,947,000280,250,000273,228,000267,687,000265,291,000256,198,000240,868,000231,168,000222,484,000235,344,000365,274,000356,308,000344,133,000311,737,000158,007,000145,922,000138,653,000130,467,000123,583,000113,423,000
  S&GA Expenses14.7%159,868,000139,321,000109,277,000107,816,000106,282,000103,137,00099,002,00087,865,00080,443,00075,045,00075,128,00077,972,00073,941,00069,047,00058,298,00043,973,00037,176,00036,159,00032,748,00030,751,00029,416,000
  R&D Expenses9.6%203,305,000185,516,000169,843,000164,236,000160,181,000160,916,000155,993,000151,836,000149,589,000146,306,000159,080,000161,780,000156,876,000149,647,000128,109,000113,256,000108,121,000101,996,00097,288,00092,423,00083,605,000
EBITDA100.0%--353,122,000-310,796,000--303,155,000-298,089,000-290,070,000-270,396,000-264,294,000-255,455,000-255,010,000-373,790,000-347,179,000-317,186,000-278,631,000-118,804,000-110,003,000-105,358,000-74,010,000-67,022,000-50,386,000
EBITDA Margin100.0%--235-140--30.32-26.01-25.25-19.67-34.07-29.67-28.27-43.98-22.63-15.78-10.51-3.68-3.76-3.64-1.38-1.22-0.81
Interest Expenses-2,624,000--------4,847,0008,021,00010,002,00012,391,0009,957,0008,207,0007,822,0007,793,0006,283,0004,741,0003,980,0002,104,000
Earnings Before Taxes75.2%-87,678,000-354,232,000-311,926,000-311,535,000-304,379,000-304,176,000-297,836,000-278,596,000-272,299,000-266,530,000-270,239,000-391,306,000-365,413,000-332,189,000-290,162,000-128,740,000-119,910,000-113,755,000-80,520,000-71,626,000-53,107,000
EBT Margin100.0%--236-140-98.93-30.44-26.54-25.92-20.26-35.10-30.96-29.96-46.04-23.82-16.53-10.94-3.99-4.10-3.93-1.50-1.30-0.85
Net Income75.3%-87,623,000-354,176,000-311,901,000-311,784,000-304,628,000-303,773,000-297,386,000-277,777,000-271,387,000-266,268,000-247,752,000-368,918,000-343,156,000-309,955,000-290,170,000-128,810,000-119,951,000-113,782,000-80,546,000-71,638,000-53,111,000
Net Income Margin100.0%--236-140-99.01-30.46-26.51-25.88-20.20-34.98-30.93-27.47-43.41-22.37-15.42-10.94-3.99-4.10-3.93-1.50-1.30-0.85
Free Cashflow100.0%--230,654,000-207,537,000-279,869,000-275,826,000-250,299,000-237,030,000-159,433,000-156,849,000-327,213,000-323,267,000-427,367,000-427,782,000-265,190,000-253,824,000-142,002,000-98,299,000-90,182,000-84,462,000-71,525,000-93,747,000
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets10.8%503454514584632680735732778815858613652664682259300331345382175
  Current Assets20.8%402333398445491537596722768806847607640652669247287317342380172
    Cash Equivalents-42.5%49.0085.0042.0032.00147532590713756778818578610624664240280313338375139
  Inventory-3.00--------------------
  Net PPE2.2%11.0011.0011.0011.0011.0011.0012.007.006.005.005.005.004.004.003.003.003.003.001.001.001.00
  Current Liabilities129.1%12555.0059.0051.0046.0044.0054.0012112111411947.0047.0020119275.0068.0061.0056.0063.0056.00
  Long Term Debt-73.00---------------80.0080.0079.0079.0079.00
    LT Debt, Non Current--------------15615575.00--79.00--
Shareholder's Equity166.8%87.00-130-65.695.0069.00128186256314369417186232229257---15.0038.00-
  Retained Earnings11.5%-1,490-1,683-1,567-1,482-1,403-1,329-1,255-1,170-1,098-1,025-958-892-827-759-710-523-483-449-420-394-363
  Additional Paid-In Capital1.6%1,5781,5531,5021,4871,4721,4571,4421,4261,4121,3951,3761,0781,059988967456450445435432196
Shares Outstanding2.0%38.0037.00-37.0036.0036.0036.0036.0036.0036.0034.0034.0033.0033.0030.0030.0030.0030.0028.0027.0026.00
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Last 12 Months)
(In Thousands)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations-9.1%-248,337-227,531-204,267-276,773-272,397-248,875-235,701-157,909-155,844-326,178-322,340-426,575-426,817-263,592-251,151-139,273-95,796-88,494-83,783-71,019-93,192
  Share Based Compensation8.0%87,84381,34458,73158,98058,19157,57156,80653,52951,45253,00557,63357,97551,77541,46126,38116,85714,22312,29210,5509,5838,382
Cashflow From Investing125.4%59,417-233,881-345,164-405,863-337,399-1,424-1,329-1,524-1,005-1,035-927-792-965-1,598-2,673-2,729-2,503-1,688-679-505-554
Cashflow From Financing530.4%90,60914,3731,4851,3421,2434,6549,138294,382302,137480,349477,093765,481757,752576,622580,3586,966240,072297,301292,472292,109167,246

RETA Income Statement

2023-06-30
Unaudited Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenues    
Total revenues$ 22,746$ 762$ 22,941$ 1,677
Operating cost and expenses    
Cost of products sold84608460
Research and development57,12039,331112,59779,136
Selling, general and administrative45,69025,143100,57549,984
Litigation settlement11,000 11,000 
Depreciation293273581581
Total operating cost and expenses114,94964,747225,599129,701
Other income (expense), net285,201(9,571)279,539(19,343)
Income (loss) from operations192,998(73,556)76,881(147,367)
Benefit from (provision for) taxes on income010(30)
Net income (loss)$ 192,998$ (73,555)$ 76,881$ (147,397)
Net income (loss) per share - basic$ 5.12$ (2.02)$ 2.06$ (4.04)
Net income (loss) per share - diluted$ 4.65$ (2.02)$ 1.89$ (4.04)
Weighted-average number of common shares used in net income (loss) per share - basic37,671,67836,467,80237,311,87236,440,364
Weighted-average number of common shares used in net income (loss) per share - diluted41,506,90036,467,80240,758,92936,440,364
Product revenues, net    
Revenues    
Total revenues$ 20,038$ 0$ 20,038$ 0
License and milestone    
Revenues    
Total revenues075401,648
Other revenue    
Revenues    
Total revenues$ 2,708$ 8$ 2,903$ 29

RETA Balance Sheet

2023-06-30
Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Assets  
Cash and cash equivalents$ 48,843$ 42,312
Marketable debt securities281,371345,202
Accounts receivable, net22,6620
Prepaid expenses and other current assets46,03110,256
Inventory, current2,9420
Total current assets401,849397,770
Property and equipment, net11,30311,179
Operating lease right-of-use-assets78,598105,258
Inventory, noncurrent10,3380
Other assets499284
Total assets502,587514,491
Liabilities and stockholders' equity (deficit)  
Accounts payable19,86018,706
Accrued direct research liabilities25,13513,836
Other current liabilities71,99124,267
Liability related to sale of future royalties, current5,6500
Operating lease liabilities, current2,4562,151
Total current liabilities125,09358,960
Opearting lease liabilities, noncurrent90,417117,313
Term Loan, net of debt issuance cost73,1300
Liability related to sale of future royalties, non-current126,656403,913
Total noncurrent liabilities290,203521,226
Commitments and contingencies
Stockholders' equity (deficit):  
Additional paid-in capital1,577,9041,501,800
Accumulated deficit(1,490,651)(1,567,532)
Total stockholders' equity (deficit)87,291(65,695)
Total liabilities and stockholders' equity (deficit)502,587514,491
Common Stock A  
Stockholders' equity (deficit):  
Common stock value3332
Common Stock B  
Stockholders' equity (deficit):  
Common stock value$ 5$ 5
J. Warren Huff
350
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.